Pfizer/Oxford Have Isolated 2,000 Proteins In Search For Alzheimer's Markers
Executive Summary
Pfizer and Oxford GlycoSciences are evaluating 2,000 proteins isolated from Alzheimer's disease patients as potential biomarkers, Oxford Chief Scientific Officer Raj Parekh, PhD, reported at an FDA/National Institutes of Health conference on Biomarkers and Surrogate Endpoints held April 15 in Bethesda, Md.